Abstract:A principal goal of drug discovery project is to design molecules that can tightly and selectively bind to the target protein receptor. Accurate prediction of protein-ligand binding free energies is therefore of central importance in computational chemistry and computer aided drug design. Multiple recent improvements in computing power, classical force field accuracy, enhanced sampling methods, and simulation setup have enabled accurate and reliable calculations of protein-ligands binding free energies, and position free energy calculations to play a guiding role in small molecule drug discovery. In this Account, we outline the relevant methodological advances, including the REST2 (Replica Exchange with Solute Temperting) enhanced sampling, the incorporation of REST2 sampling with convential FEP (Free Energy Perturbation) through FEP/REST, the OPLS3 force field, and the advanced simulation setup that constitute our FEP+ approach, followed by the presentation of extensive comparisons with experiment, demonstrating sufficient accuracy in potency prediction (better than 1 kcal/mol) to substantially impact lead optimization campaigns. The limitations of the current FEP+ implementation and best practices in drug discovery applications are also discussed followed by the future methodology development plans to address those limitations. We then report results from a recent drug discovery project, in which several thousand FEP+ calculations were successfully deployed to simultaneously optimize potency, selectivity, and solubility, illustrating the power of the approach to solve challenging drug design problems. The capabilities of free energy calculations to accurately predict potency and selectivity have led to the advance of ongoing drug discovery projects, in challenging situations where alternative approaches would have great difficulties. The ability to effectively carry out projects evaluating tens of thousands, or hundreds of thousands, of proposed drug candidates, is potentially transformative in enabling hard to drug targets to be attacked, and in facilitating the development of superior compounds, in various dimensions, for a wide range of targets. More effective integration of FEP+ calculations into the drug discovery process will ensure that the results are deployed in an optimal fashion for yielding the best possible compounds entering the clinic; this is where the greatest payoff is in the exploitation of computer driven design capabilities. A key conclusion from the work described is the surprisingly robust and accurate results that are attainable within the conventional classical simulation, fixed charge paradigm. No doubt there are individual cases that would benefit from a more sophisticated energy model or dynamical treatment, and properties other than protein-ligand binding energies may be more sensitive to these approximations. We conclude that an inflection point in the ability of MD simulations to impact drug discovery has now been attained, due to the confluence of hardware and software development along with the formulation of "good enough" theoretical methods and models.

Combined and Iterative Use of Computational Design and Directed Evolution for Protein-Ligand Binding Design

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Computational Design Of Ligand-Binding Proteins

LigEvolutioner, a New Strategy for Modification and Optimization of Lead Compounds in Receptor/Ligand Complexes

Directed evolution of specific receptor–ligand pairs for use in the creation of gene switches

Towards Structure-Based Protein Drug Design

LARMD: Integration of Bioinformatic Resources to Profile Ligand-Driven Protein Dynamics with a Case on the Activation of Estrogen Receptor.

Computational protein design with evolutionary-based and physics-inspired modeling: current and future synergies

Rational evolution for altering the ligand preference of estrogen receptor alpha

Multiple Target Drug Design Using LigBuilder 3

Protein–ligand docking using differential evolution with an adaptive mechanism

COMPUTATIONAL ENZYME DESIGN APPROACHES WITH SIGNIFICANT BIOLOGICAL OUTCOMES: PROGRESS AND CHALLENGES

Iterative approach to computational enzyme design

Rapid creation of a novel protein function by in vitro coevolution.

Coupling Protein Side-Chain and Backbone Flexibility Improves the Re-design of Protein-Ligand Specificity

Computational Design of Proteins with Novel Structure and Functions

Advancing Drug Discovery through Enhanced Free Energy Calculations

Unlocking the potential of enzyme engineering via rational computational design strategies

Computer-Aided Drug Design in Epigenetics

Ensemble-based enzyme design can recapitulate the effects of laboratory directed evolution in silico

LigBuilder V3: A Multi-Target De Novo Drug Design Approach.